Table 3 Changes of echocardiographic, biochemical and functional factors in patients treated with torasemide or furosemide.
| Torasemide | Furosemide | |||
|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | |
| Echocardiography | ||||
| LVEDV (ml) | 173 (22) | 147 (30)** | 174 (24) | 165 (34) |
| LVESV (ml) | 117 (19) | 95 (24)** | 120 (15) | 109 (33) |
| LVEF (%) | 31 (7) | 34 (7) | 31 (7) | 32 (7) |
| Plasma BNP (pg/ml) | 244 (133) | 154 (95)**† | 239 (147) | 218 (94) |
| NYHA functional class | ||||
| I/II/III | 0/7/13 | 7/12/1**† | 0/8/12 | 2/13/5* |
*p<0.05, **p<0.001 v baseline; †p<0.05 v furosemide group at 6 months.
BNP, brain natriuretic peptide; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; NYHA, New York Heart Association.